A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Tetravalent nanobodies to GPVI and CLEC-2 stimulate powerful activation of platelets at low nanomolar concentrations in flow cytometry. In contrast, trivalent nanobodies are partial agonists. The defined stoichiometry of the nanobodies will aid development of standardized platelet flow cytometry assays.
Authors
- Rachel E. Lamerton (ORCID: https://orcid.org/0000-0002-8931-7279)
- Adam F. Cunningham (ORCID: https://orcid.org/0000-0003-0248-964X)
- Steve P. Watson (ORCID: https://orcid.org/0000-0002-7846-7423)
- Eleyna M. Martin (ORCID: https://orcid.org/0000-0002-9799-4464)
- Jacqueline Perry (ORCID: https://orcid.org/0000-0002-9648-7313)
- Andrew L. Frelinger (ORCID: https://orcid.org/0000-0002-6871-7441)
Institutions
- Harvard University (US)
- University College Birmingham (GB)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Birmingham (GB)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.rpth.2025.103196
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00